Welcome to our dedicated page for Candel Therapeutics news (Ticker: CADL), a resource for investors and traders seeking the latest updates and insights on Candel Therapeutics stock.
Candel Therapeutics, Inc. (CADL) is a Massachusetts-based biotechnology company, also known as Advantagene, Inc., specializing in the development of cutting-edge immuno-oncology platforms aimed at treating solid tumors. The company's focus is on leveraging the body's immune system to combat cancer through innovative viral immunotherapies.
At the core of Candel Therapeutics' technology are two proprietary platforms: the Gene Mediated Cytotoxic Immunotherapy (GMCI™) platform and the RQNestin34.5 platform. Designed as an 'off-the-shelf' solution, GMCI™ aims to generate a personalized and precise immune response against cancer, utilizing the patient's own immune system. The RQNestin34.5 platform, on the other hand, is centered around the use of genetically modified herpes simplex virus (HSV) constructs to target and destroy cancer cells.
As a clinical-stage biopharmaceutical company, Candel Therapeutics is dedicated to translating its scientific advancements into viable treatments for patients. The company has made substantial progress with its platforms, demonstrating promising results in clinical studies aiming to establish the efficacy and safety of these novel therapies.
Among the company's recent highlights is its presentation at the American Society of Clinical Oncology (ASCO), where it shared significant updates on its ongoing projects. Candel Therapeutics continues to engage in strategic partnerships and collaborations to advance its mission of making effective cancer treatments accessible to patients globally.
Candel Therapeutics is committed to maintaining robust investor relations, offering transparent updates and clear communication about its financial health, project milestones, and future directions. The company's leadership frequently engages with stakeholders to ensure alignment with their goals and expectations.
For the latest news and detailed financial information, investors and interested parties can contact Theodore Jenkins, Vice President of Investor Relations and Business Development, at tjenkins@candeltx.com or Kyle Evans, Account Director at ICR Westwicke, at CandelPR@westwicke.com.
Candel Therapeutics presented updated results from its phase 1 trial of CAN-3110 for recurrent high-grade glioma (rHGG) at the SNO Annual Meeting. The trial involved 41 patients, with no dose-limiting toxicities observed. The median overall survival was reported at 11.6 months post-administration, with one patient achieving a complete response lasting over a year. The treatment showed positive effects on T cell activation and diversity, suggesting a shift in the tumor microenvironment. Future studies will explore the impact of multiple CAN-3110 injections on survival.
Candel Therapeutics, Inc. (Nasdaq: CADL) presented late-breaking data from a phase 1 trial of its lead viral immunotherapy, CAN-2409, combined with nivolumab for high-grade glioma patients. The combination showed promising results, being well tolerated with no significant added toxicity. It induced systemic immune activation and improved median overall survival (mOS) for patients with methylated MGMT promoter to 30.6 months after gross total resection. The trial supports the potential therapeutic synergy between CAN-2409 and immune checkpoint inhibitors.
Candel Therapeutics (Nasdaq: CADL) reported Q3 2022 results, achieving significant developments, including a partnership with the University of Pennsylvania's Center for Cellular Immunotherapies to explore viral immunotherapy and CAR-T cell combinations. The Company secured orphan drug designation for CAN-2409 in glioma and added new leadership. Financially, Q3 net loss decreased to $8.7 million from $16.2 million YoY. Cash position stood at $77.2 million, sufficient to sustain operations through Q1 2024.
Candel Therapeutics (Nasdaq: CADL) announced new clinical data to be presented at the 37th Annual Meeting of the Society for Immunotherapy of Cancer and the 27th Annual Meeting of the Society for Neuro-Oncology, scheduled for November 11 and 18, 2022, respectively. Key highlights include presentations on CAN-2409's efficacy in high-grade glioma and its impact on tumor microenvironments. These findings could significantly advance understanding of viral immunotherapy in treating cancer.
On November 1, 2022, Candel Therapeutics, Inc. (Nasdaq: CADL) announced that its CEO, Paul Peter Tak, will participate in several investor conferences this month. The events include the Credit Suisse 31st Annual Healthcare Conference on November 8 at 8:35 am PT, the BMO Biopharma Spotlight Series: Oncology Day on November 9 at 10:00 am ET, and the Jefferies London Healthcare Conference on November 16 at 7:25 am GMT. For webcast recordings, visit Candel's website. Candel focuses on developing viral immunotherapies for cancer using genetically modified viruses to enhance anti-tumor responses.
Candel Therapeutics (Nasdaq: CADL) announced a collaboration with the University of Pennsylvania to explore novel viral immunotherapies aimed at enhancing CAR-T cell therapies for solid tumors. Utilizing Candel’s enLIGHTEN Discovery Platform, the research will focus on herpes simplex virus vectors to improve T-cell efficacy. Both organizations will maintain rights to their respective programs and the ability to advance these therapies into clinical trials. This partnership aims to address significant barriers in the solid tumor microenvironment to improve treatment outcomes.
Candel Therapeutics (Nasdaq: CADL) announced on September 15, 2022, that the European Medicines Agency (EMA) COMP issued a positive opinion for orphan drug designation of CAN-2409 to treat glioma. This follows the fast track designation from the FDA in June 2021. CAN-2409, a genetically modified adenovirus, is in phase 2 and 3 trials for various cancers. The orphan drug designation provides potential benefits such as a 10-year marketing exclusivity in the EU and reduced fees during development.
Candel Therapeutics (Nasdaq: CADL) announces the appointment of Jason A. Amello as Chief Financial Officer and Garrett Nichols, MD, MS as Chief Medical Officer, effective September 21, 2022. Mr. Amello replaces John Canepa, who is moving on for personal reasons. Both new leaders bring extensive experience in biopharmaceuticals, with Amello's previous roles including CFO at Saniona AB and Akebia Therapeutics, and Nichols having served as CMO at Istari Oncology. Their leadership is expected to enhance Candel's efforts in developing oncolytic viral immunotherapies for cancer treatment.
Candel Therapeutics, Inc. (Nasdaq: CADL) announced participation in two investor conferences. CEO Paul Peter Tak will attend Citi's 17th Annual BioPharma Conference in Boston on September 7. Candel will also present at the H.C. Wainwright 24th Annual Global Investment Conference via webcast on September 12 at 7:00 AM ET. The company focuses on oncolytic viral immunotherapies for cancer treatment, with lead products CAN-2409 and CAN-3110. A webcast of the latter presentation will be archived for up to 90 days. Visit Candel's website for more details.
Candel Therapeutics, Inc. (Nasdaq: CADL) reported its Q2 2022 financial results, revealing a net loss of $4.1 million, a significant decrease from $17.1 million in Q2 2021. The company maintains a strong cash position of $86.8 million, sufficient to fund operations into Q1 2024. Candel announced a promising 87.5% disease control rate from its phase 2 clinical trial of CAN-2409 in NSCLC at ASCO 2022. Upcoming milestones include phase 3 trials for high-grade glioma and updates on their enLIGHTEN™ Discovery Platform.
FAQ
What is the current stock price of Candel Therapeutics (CADL)?
What is the market cap of Candel Therapeutics (CADL)?
What does Candel Therapeutics, Inc. specialize in?
What are the main platforms developed by Candel Therapeutics?
How does the GMCI™ platform work?
What is unique about the RQNestin34.5 platform?
Is Candel Therapeutics a clinical-stage company?
What recent achievements has Candel Therapeutics made?
Who can I contact for investor relations at Candel Therapeutics?
Who handles media inquiries for Candel Therapeutics?
What types of cancer are targeted by Candel Therapeutics' platforms?
Where is Candel Therapeutics based?
